Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1980 2
1983 3
1984 3
1985 4
1986 3
1987 3
1988 2
1989 3
1990 4
1991 2
1992 2
1993 4
1994 1
1995 1
1996 6
1997 1
1998 3
1999 6
2000 3
2001 9
2002 11
2003 6
2004 9
2005 11
2006 18
2007 21
2008 12
2009 11
2010 20
2011 23
2012 25
2013 39
2014 46
2015 49
2016 66
2017 51
2018 70
2019 57
2020 90
2021 98
2022 72
2023 60
2024 81
2025 101
2026 87

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,077 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, Lindsay J, Baker RI, Suzuki K, Kosugi H, Levin MD, Beksac M, Stockerl-Goldstein K, Oriol A, Mikala G, Garate G, Theunissen K, Spicka I, Mylin AK, Bringhen S, Uttervall K, Pula B, Medvedova E, Cowan AJ, Moreau P, Mateos MV, Goldschmidt H, Ahmadi T, Sha L, Cortoos A, Katz EG, Rousseau E, Li L, Dennis RM, Carson R, Rajkumar SV; AQUILA Investigators. Dimopoulos MA, et al. N Engl J Med. 2025 May 8;392(18):1777-1788. doi: 10.1056/NEJMoa2409029. Epub 2024 Dec 9. N Engl J Med. 2025. PMID: 39652675 Clinical Trial.
BACKGROUND: Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a precursor disease of active mult …
BACKGROUND: Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are n …
Smoldering multiple myeloma current treatment algorithms.
Rajkumar SV, Kumar S, Lonial S, Mateos MV. Rajkumar SV, et al. Blood Cancer J. 2022 Sep 5;12(9):129. doi: 10.1038/s41408-022-00719-0. Blood Cancer J. 2022. PMID: 36064707 Free PMC article. Review.
Smoldering multiple myeloma (SMM) is an asymptomatic condition that occupies a space between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) along the spectrum of clonal plasma cell proliferative disorders. .. …
Smoldering multiple myeloma (SMM) is an asymptomatic condition that occupies a space between monoclonal gammopathy of u …
Smoldering multiple myeloma - Past, present, and future.
Mann H, Katiyar V, Varga C, Comenzo RL. Mann H, et al. Blood Rev. 2022 Mar;52:100869. doi: 10.1016/j.blre.2021.100869. Epub 2021 Jul 22. Blood Rev. 2022. PMID: 34312016 Review.
Smoldering multiple myeloma (SMM) routinely precedes the development of multiple myeloma. ...
Smoldering multiple myeloma (SMM) routinely precedes the development of multiple myeloma. ...
Smoldering multiple myeloma.
Rajkumar SV, Landgren O, Mateos MV. Rajkumar SV, et al. Blood. 2015 May 14;125(20):3069-75. doi: 10.1182/blood-2014-09-568899. Epub 2015 Apr 2. Blood. 2015. PMID: 25838344 Free PMC article. Review.
Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. SMM is distinguished from monoclonal gammopathy of undetermined significance by a much higher risk of progression to multiple myeloma (MM). ...
Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. SMM is distinguished from monoclonal …
Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.
Rajkumar SV, Bergsagel PL, Kumar S. Rajkumar SV, et al. Hematol Oncol Clin North Am. 2024 Apr;38(2):293-303. doi: 10.1016/j.hoc.2023.12.001. Epub 2023 Dec 28. Hematol Oncol Clin North Am. 2024. PMID: 38158241 Free PMC article. Review.
Smoldering multiple myeloma (SMM) is an intermediate clinical stage in the spectrum of monoclonal plasma cell disorders. It represents a heterogeneous clinically defined condition in which some patients (approximately 50%) have monoclonal gammopathy of undete …
Smoldering multiple myeloma (SMM) is an intermediate clinical stage in the spectrum of monoclonal plasma cell disorders …
Understanding high-risk smoldering multiple myeloma.
Kreiniz N, Gertz MA. Kreiniz N, et al. Leuk Lymphoma. 2023 Jul-Aug;64(8):1361-1372. doi: 10.1080/10428194.2023.2216818. Epub 2023 May 25. Leuk Lymphoma. 2023. PMID: 37229535 Review.
Smoldering multiple myeloma (SMM) is an asymptomatic condition with heterogeneous biology and various risks of progression to symptomatic disease. ...
Smoldering multiple myeloma (SMM) is an asymptomatic condition with heterogeneous biology and various risks of progress …
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Lakshman A, et al. Blood Cancer J. 2018 Jun 12;8(6):59. doi: 10.1038/s41408-018-0077-4. Blood Cancer J. 2018. PMID: 29895887 Free PMC article.
In 2014, the International Myeloma Working Group reclassified patients with smoldering multiple myeloma (SMM) and bone marrow-plasma cell percentage (BMPC%) 60%, or serum free light chain ratio (FLCr) 100 or >1 focal lesion on magnetic resonance …
In 2014, the International Myeloma Working Group reclassified patients with smoldering multiple myeloma (SMM) an …
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.
Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV. Lonial S, et al. J Clin Oncol. 2020 Apr 10;38(11):1126-1137. doi: 10.1200/JCO.19.01740. Epub 2019 Oct 25. J Clin Oncol. 2020. PMID: 31652094 Free PMC article. Clinical Trial.
PURPOSE: Observation is the current standard of care for smoldering multiple myeloma. We hypothesized that early intervention with lenalidomide could delay progression to symptomatic multiple myeloma. ...CONCLUSION: Early intervention with lenal …
PURPOSE: Observation is the current standard of care for smoldering multiple myeloma. We hypothesized that early interv …
Smoldering multiple myeloma: to treat or not to treat.
Gentile M, Offidani M, Vigna E, Corvatta L, Recchia AG, Morabito L, Martino M, Morabito F, Gentili S. Gentile M, et al. Expert Opin Pharmacother. 2015 Apr;16(6):785-90. doi: 10.1517/14656566.2015.1007952. Epub 2015 Feb 8. Expert Opin Pharmacother. 2015. PMID: 25659943 Review.
INTRODUCTION: Smoldering multiple myeloma (SMM) is an asymptomatic disorder characterized by the presence of 30 g/l serum M-protein and/or 10% bone marrow plasma cell infiltration. The progression risk to active multiple myeloma (MM) is not …
INTRODUCTION: Smoldering multiple myeloma (SMM) is an asymptomatic disorder characterized by the presence of 30 g/l s …
How I approach smoldering multiple myeloma.
Vaxman I, Gertz MA. Vaxman I, et al. Blood. 2022 Aug 25;140(8):828-838. doi: 10.1182/blood.2021011670. Blood. 2022. PMID: 35576526 Free PMC article. Review.
The current standard of care in smoldering multiple myeloma (SMM) is close surveillance, outside of clinical trials. Efforts are being made to understand the pathobiologic process that leads to the progression of SMM to active MM. ...We describe 2 cases in wh …
The current standard of care in smoldering multiple myeloma (SMM) is close surveillance, outside of clinical trials. Ef …
1,077 results